Direct Delivery of piggyBac CD19 CAR T Cells Has Potent Anti-tumor Activity against ALL Cells in CNS in a Xenograft Mouse Model
Kuniaki Tanaka, Itaru Kato, Miyuki Tanaka, Daisuke Morita, Kazuyuki Matsuda, Yoshiyuki Takahashi, Tatsutoshi Nakahata, Katsutsugu Umeda, Hidefumi Hiramatsu, Souichi Adachi, Junko Takita, Yozo Nakazawa
Abstract
CD19 CAR T cells by i.v. had partial effects, whereas all CAR T i.c.v.-delivered mice had eliminated ALL in CNS. Although some CAR T i.c.v.-delivered mice showed transient changes of clinical symptoms during the first few days after treatment, none of CAR T i.c.v.-delivered mice displayed fatal adverse events. In this study, we demonstrated that direct delivery into CNS of CAR T cells is a possible therapeutic approach with the xenograft mouse model.
Topics & Concepts
CD19Cancer researchTumor cellsChemistryCell biologyBiologyCellBiochemistryCAR-T cell therapy researchVirus-based gene therapy researchViral Infectious Diseases and Gene Expression in Insects